B/F/TAF
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
HIV-1-infection
Conditions
HIV-1-infection
Trial Timeline
Dec 13, 2023 → Apr 23, 2025
NCT ID
NCT06104306About B/F/TAF
B/F/TAF is a approved stage product being developed by Gilead Sciences for HIV-1-infection. The current trial status is completed. This product is registered under clinical trial identifier NCT06104306. Target conditions include HIV-1-infection.
What happened to similar drugs?
11 of 18 similar drugs in HIV-1-infection were approved
Approved (11) Terminated (3) Active (6)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07055451 | Phase 1 | Recruiting |
| NCT06104306 | Approved | Completed |
| NCT05147740 | Approved | UNKNOWN |
| NCT03960645 | Phase 1 | Completed |
| NCT03797014 | Approved | Completed |
| NCT03580668 | Pre-clinical | Completed |
| NCT03405935 | Phase 3 | Completed |
Competing Products
20 competing products in HIV-1-infection